UMIN-CTR Clinical Trial

The primary outcome was positive symptom score, as measured by PANSS. GAF and measures of cognitive biases were secondary outcomes. The severity of PANSS positive symptoms declined significantly in the TAU？+？MCT treatment group compared with the TAU group. GAF also showed significantly greater improvement in the TAU？+？MCT group compared with the TAU group. There was also a trend for greater efficacy of MCT on cognitive biases.

1. The people fulfilled criteria for a schizophrenia, schizotypal and delusional disorders according to ICD-10 (F20-F29).
2. They were 20-60 years old, male and female
3. The people fulfilled of criteria for a schizophrenia spectrum disorder according to the Mini-International Neuropsychiatric Interview (M.I.N.I.)
4. A minimal symptom threshold was defined for inclusion criteria: above 3 on the delusion component of the PANSS.
5. Exclusion criteria were patients who had an intellectual disability, developmental disorder, dementia deficiency, personality disorder, organic brain damage, or history of substance abuse.
6. People who scored above 5 on the PANSS hostility item, or who scored above 6 on the suspiciousness item were excluded.

1. 78 people who fulfilled the criteria of ICD-10 were recruited.
2. 13 people were estimated below 2 points in delusion of PANSS.
3. Ages of 6 people failed to fulfill the condition.
4. 5 people failed to fulfill the condition of M.I.N.I.
5. 1 people was estimated above 5 points in hostility of PANSS.
6. 3 in 53 people who fulfilled all of the conditions declined to participate in this research.
7. 50 people were randomly divided into MCT+TAU group (n=24) and TAU group (n=26).

nothing

PANSS
GAF
CBQp
BCIS
BDI-2
EQ-5D-5L
Rosenberg Self-esteem Scale